Supyra®

S Kant Healthcare

Product category	Intermittent preventive treatment (sulfadoxine-pyrimethamine + amodiaquine)
Therapeutic indication	Seasonal Malaria chemoprevention (SMC) for children 3 to 59 months in eligible regions (Sahel region in Sub-Saharan Africa)
Dosing	Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months
Efficacy	75% reduction in malaria episodes in pivotal trials
Key features	Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission 2-year shelf life
Challenges	Drug distribution to healthy subjects mainly via door-to-door campaigns
Status	WHO prequalification obtained in April 2021 2^nd taste-masked and dispersible SPAQ formulation prequalified by WHO Registered in 6 countries; ongoing in 5 other countries 18 million treatments delivered in 2021
Next milestone	Extension of the recommendation for children up to their 10^th birthday Validation of the dose and development of a specific packaging for children from 5 years old up until their 10^th birthday Exploration of expanded SMC coverage by adding a fifth monthly round of treatment in areas with longer seasonal transmission Confirmation of potential efficacy and adoption in areas outside of the Sahel region
MMV Project Director	Dr André-Marie Tchouatieu